Thitapond Nulek1, Rachan Klaysri1, Ruel Cedeno1, Phattananawee Nalaoh2, Sareeya Bureekaew1, Vinich Promarak2, Adrian E Flood1. 1. Department of Chemical and Biomolecular Engineering, School of Energy Science and Engineering, Vidyasirimedhi Institute of Science and Technology, 555 Moo 1, Payupnai, Wang Chan, 21210 Rayong, Thailand. 2. Department of Materials Science and Engineering, School of Molecular Science and Engineering, Vidyasirimedhi Institute of Science and Technology, 555 Moo 1, Payupnai, Wang Chan, 21210 Rayong, Thailand.
Abstract
Chirality plays an important role in the pharmaceutical industry since the two enantiomers of a drug molecule usually display significantly different bioactivities, and hence, most products are produced as pure enantiomers. However, many drug precursors are synthesized as racemates, and hence, enantioseparation has become a significant process in the industry. Cocrystallization is one of the attractive crystallization approaches to obtain the desired enantiomer from racemic compounds. In this work, we propose a chiral resolution route for an antiepileptic drug, S-etiracetam (S-ETI), via enantiospecific cocrystallization with S-2-chloro-S-mandelic acid (CLMA) as a coformer. The experiments indicate that the system is highly enantiospecific; S-2CLMA cocrystallizes only with S-ETI but not with R-ETI or RS-ETI. Therefore, the chiral purification of S-ETI can be achieved efficiently with a 69.1% yield and close to 100% enantiopurity from the racemic solution. Additionally, structural simulations of the S-ETI:S-2CLMA cocrystal reveal that the cocrystal structure has higher thermodynamic stability than that of R-ETI:S-2CLMA by about 5.5 kcal/mol (per cocrystal formula unit), which helps to confirm the favorability of the enantiospecification in this system.
Chirality plays an important role in the pharmaceutical industry since the two enantiomers of a drug molecule usually display significantly different bioactivities, and hence, most products are produced as pure enantiomers. However, many drug precursors are synthesized as racemates, and hence, enantioseparation has become a significant process in the industry. Cocrystallization is one of the attractive crystallization approaches to obtain the desired enantiomer from racemic compounds. In this work, we propose a chiral resolution route for an antiepileptic drug, S-etiracetam (S-ETI), via enantiospecific cocrystallization with S-2-chloro-S-mandelic acid (CLMA) as a coformer. The experiments indicate that the system is highly enantiospecific; S-2CLMA cocrystallizes only with S-ETI but not with R-ETI or RS-ETI. Therefore, the chiral purification of S-ETI can be achieved efficiently with a 69.1% yield and close to 100% enantiopurity from the racemic solution. Additionally, structural simulations of the S-ETI:S-2CLMA cocrystal reveal that the cocrystal structure has higher thermodynamic stability than that of R-ETI:S-2CLMA by about 5.5 kcal/mol (per cocrystal formula unit), which helps to confirm the favorability of the enantiospecification in this system.
Enantioseparation
processes are a crucial step in the pharmaceutical
industry since new active pharmaceutical ingredients (APIs) are required
to have high enantiopurity due to the possible adverse side effects
of the undesired enantiomer.[1] Preferential
crystallization has been an easy and very effective method to separate
the desired enantiomer from the undesired one.[2,3] Unfortunately,
this technique requires enantiomers to crystallize as a conglomerate-forming
system, which is only found in ∼5–10% of all chiral
systems.[4] Thus, diastereomeric salt formation
is still widely used in the industry because it can be used with racemates,
which are 90–95% of chiral crystalline compounds.[4,5]An alternative chiral resolution method, cocrystallization
using
a chiral coformer, has been proposed for nonionizable compounds, especially
racemates, that cannot easily form a salt.[6] Enantiospecific cocrystallization was first introduced by Springuel
and Leyssens.[7] In this process, the coformer
only cocrystallizes with one of the two enantiomers of the API, and
the process can be performed with high enantiopurity and yield. However,
the separation also can be done by diastereomeric cocrystallization,
in which the coformer interacts with both enantiomers. Obviously,
enantiospecific cocrystallization is more attractive since it is easier
to design the crystallization process as the number of solid phases
in the phase diagram is reduced.[8] Even
though chiral resolution via cocrystallization has a common principle
with the diastereomeric salt formation technique, adding another chiral
compound to form a new crystalline product with a specific enantiomer,
the mechanism and outcome are very different. The cocrystallization
technique relies on intermolecular interactions between the API and
coformer, such as hydrogen bonding, halogen bonding, CH−π
interactions,[9] and van der Waals forces.[8] In diastereomeric salt formation, the API and
resolving agent interact via strong ionic bonds.[8] Therefore, enantiopurification via cocrystallization is
a worthwhile approach for resolution of racemic mixtures since the
cocrystal formation does not alter the speciation of the compound
in the crystallization step, maintaining its biological activity.[6] Another significant difference between these
two procedures is that the cocrystallization technique commonly behaves
as an enantiospecific system,[7,8,10,11] in contrast with salt formation
where both diastereomers can form but one is typically more stable
than the other.[8] Moreover, the hydrogen
bonding pattern in cocrystals tends to be weaker and far more directional
and thus dependent on the stereochemistry of the API than the ionic
bond in salt formation.[8] Lastly, the separation
process of cocrystals is much easier than that in salt formation because
of the weaker bonds involved in cocrystals.Levetiracetam or S-2-(2-oxopyrrolidin-1-yl)butanamide
is an antiepileptic drug sold under the name Keppra. It is used for
treating the symptoms of epileptic seizures that can also occur with
patients who have primary or secondary tumors;[12] however, there is no report on the pharmaceutical efficacy
of its enantiomer, R-etiracetam (R-ETI).[13] Furthermore, S-etiracetam (S-ETI) is also used in combination
with other medicines to treat individual types of seizures.[14] Naturally, S-ETI is a chiral
drug that crystallizes as a racemic compound rather than as a conglomerate.
Consequently, direct preferential crystallization is expected to be
difficult to apply to this system unless a convenient conglomerate
salt or derivative can be found. Springuel and Leyssens have successfully
resolved S-ETI from its racemic mixture with 70%
yield using S-mandelic acid as a coformer via enantiospecific
cocrystallization.[7] Cocrystallization using S-ibuprofen has also resolved S-ETI from
its racemic mixture with 87.6% ee.[10] In
another study, the racemate is converted to an ionic cocrystal by
adding a suitable amount of ZnCl2 to the etiracetam solution,
which then facilitates chiral resolution.[15] In addition, cocrystals of S-ETI with other compounds
have also been found, with coformers including R-α-ketoglutaric
acid[11] and d-tartaric acid.[16] Recently, enantioseparation has been achieved
for a range of halogenated mandelic acids using cocrystallization
with levetiracetam as a resolving agent.[17] Although one of the two diastereomers involved in the separation
of the halogenated mandelic acid enantiomers will be similar to that
used in the separation of the levetiracetam enantiomers, the potential
second diastereomeric cocrystal in the two cases is distinct, which
means that the ability to use enantioseparation in the first case
does not indicate that the second case will also be successful. This
led to a question whether halogenated mandelic acids could be a viable
resolving agent for the enantiopurification of levetiracetam.In cocrystallization, although there are heuristic rules for selecting
suitable coformers,[18] the screening process
is still generally done via a trial-and-error approach. This shows
that further understanding of the molecular origins governing the
chiral discrimination mechanism in cocrystal systems is needed. Thus,
the purposes of this study are discovering a new chiral cocrystal
system and performing chiral resolution via cocrystallization. Moreover,
the study aims to gain further understanding of the molecular origins
governing the chiral discrimination mechanism in this cocrystal system.In this work, we demonstrate an enantiopurification route for RS-ETI using the chiral coformer 2-chloro-S-mandelic acid (S-2CLMA), an important cardiovascular
drug precursor.[19] Characterizations of
the new cocrystal and chiral resolution via the cocrystallization
technique are illustrated in this paper. In addition, we elucidate
for the first time the crystal structure of this chiral cocrystal
by X-ray crystallography and analyze the intermolecular interactions
via density functional theory (DFT) calculations to gain more insights
into the observed enantiospecific behavior. The techniques and insights
presented here could be useful to guide the design of enantiospecific
cocrystallization and obtain an idea for screening of suitable coformers.
Materials
Starting Materials
2-Chloro-S-mandelic acid (S-2CLMA)
and 2-chloro-R-mandelic acid (R-2CLMA)
were purchased
from TCI with a purity of >98%. Racemic etiracetam (RS-ETI) was obtained by racemization of S-ETI purchased
from Acros following a procedure similar to that of Springuel et al.[20] Starting with 2 g of levetiracetam, 0.05 equiv
of sodium methoxide was added to 2 mL of methanol. The solution was
stirred at 50 °C for 24 h using a condenser to return any solvent
that evaporated. Then, the solution was cooled in a bath at 5 °C
to let the compound crystallize. The solid phase was filtered and
washed with cold methanol before drying in a vacuum oven. HPLC and
NMR were used to confirm that complete racemization had occurred with
no degradation of the etiracetam. Deionized (DI) water (PURELAB Classic,
15.0 MΩ cm, type II) and acetonitrile (Honeywell, HPLC grade)
were used as solvents without further purification.
Screening Experiment
Screening experiments
of two API compounds, S-ETI and RS-oxiracetam, were done with various coformers using the neat grinding
technique. An equimolar ratio of the mentioned APIs with various coformers
was ground for either 2 or 3 h; then, the solid was characterized
by XRPD. The pairs that have been examined are given in Table S1.
Liquid-Assisted
Grinding for Cocrystal Creation
The cocrystal for characterization
of the stable form was prepared
using a liquid-assisted grinding technique with an equimolar ratio
of S-ETI and S-2CLMA in the presence
of a small amount of acetonitrile. In the experiment, 0.268 mmol S-2CLMA and S-ETI were mixed in a grinding
tube with an addition of 10 μL of acetonitrile and two milling
balls (7 mm diameter). The mixture was then ground using a Retsch
MM200 ball mill at a frequency of 25 rounds/s for 60 min. Then, the
solid was dried and characterized by XRPD and TGA.
Single Crystal of the Levetiracetam-2-Chloro-S-Mandelic Acid Cocrystal
A total of 0.2 g of S-ETI:S-2CLMA cocrystal from multiple cocrystal
preparations was dissolved in 1 mL of chloroform (boiling point of
61.2 °C). After the cocrystal was completely dissolved, 1 mL
of hexane (boiling point of 69 °C) was added as an antisolvent.
Then, the vial was left under stirring under ambient conditions with
the cap loosened to allow the solvents to slowly evaporate. Since
the chloroform solvent has a lower boiling point than that of the
antisolvent hexane, the molar ratio of the antisolvent to the solvent
increased during the evaporation process. Single crystals formed after
some of the solvent mixture evaporated. Finally, a single crystal
suitable for X-ray crystallography was obtained.
Chiral Resolution
A total of 114
mg of racemic ETI was mixed with S-2CLMA in 1:1 mole
ratio. Then, the solid mixture was dissolved in 0.5 mL of acetonitrile
at 65 °C for 35 min. After the suspension was completely dissolved,
the solution was cooled to −14 °C. The S-ETI:S-2CLMA cocrystal from liquid-assisted grinding
was seeded into the vial after the solution reached the crystallization
temperature. A cocrystal formed immediately after seeding, but to
get a satisfying yield, the crystalline solid was collected 48 h after
seeding. Then, the crystalline solid was washed with 2 mL of cooled
diethyl ether and dried at 40 °C under vacuum. To analyze the
enantiomeric excess and yield of the resolved enantiomer (S-ETI), 1 mg of the cocrystal was stirred for 1 h in 150
μL of diethyl ether, which is an appropriate amount of solvent
to dissolve most of the S-2CLMA from the cocrystal
while obtaining a good yield of S-ETI (Table S2). Diethyl ether was chosen as the solvent
for this process since the solubility of S-ETI in
this solvent is very low (less than 0.007 g/g of diethyl ether[21]) compared to the solubility of S-2CLMA (0.369 g/g of diethyl ether[22]),
which makes it suitable for separating the components of the cocrystal.
The solubilities of the components in other solvents that were considered
are shown in the Supporting Information, Table S3. Afterward, the remaining solid was filtered and analyzed
by HPLC using a Chiralcel OD column. Details of the HPLC technique
are given in the Supporting Information.
Computational Details
For solid-state
simulations, we used the experimental crystal structure of S-ETI:S-2CLMA determined in this work as
a starting geometry. To explain why R-ETI:S-2CLMA is not observed experimentally, we employed crystal
structure prediction (CSP) to scan its energy landscape via a quasi-random
search.[23] To reduce the number of trial
structures, we used a Monte Carlo procedure to preliminarily screen
low-energy interacting pairs (synthons) using the Gmmx[24] module as implemented in PCModel v10.[25] The structures were then optimized using the
Merck molecular force field (MMFF94).[26] The search is stopped when the maximum number of randomly generated
synthons reaches 10 000 or when at least one pair reaches 50
duplicates. The 10 most stable synthons were used as the initial asymmetric
unit. To generate random unit cells with a predefined space group,
we used the Pyxtal program.[27] We constrained
the initial cell volume per asymmetric unit to be comparable to that
of the S-ETI:S-2CLMA cocrystal.
To reduce the computational cost, we constrained the search space
to the most common space groups for chiral cocrystals,[28] i.e., P1, P-1, P2, P21, P21/c, and P212121. The generated unit cells were then
optimized using the semiempirical PM7 Hamiltonian with periodic boundary
conditions as implemented in MOPAC v2016,[29,30] which has been shown to have good performance in predicting thermodynamic
properties particularly for organic systems.[31,32] The structures of the five most stable candidates were further refined
using periodic density functional theory (DFT) calculations as implemented
in the CP2K package,[33] which uses a mixed
Gaussian/plane-wave (GPW) basis set. The exchange and correlation
energies were evaluated using the semilocal Perdew–Burke–Ernzerhof
(PBE) form of the generalized gradient approximation (GGA) functional
together with Grimme’s D3 van der Waals correction.[34,35] DZVP-MOLOPT basis sets and Goedecker–Teter–Hutter
(GTH) pseudopotentials were selected in the calculations.[36,37] An energy cutoff of 500 Ry and relative energy cutoff of 80 Ry were
found to be sufficient for energy convergence. Brillouin zone integration
was sampled at the Γ point, which is sufficient due to the large
size of the supercell (1 × 2 × 1 cell containing 180 atoms).
Atomic structures were optimized using the BFGS algorithm[38] until the forces acting on each atom were less
than 0.005 eV/Å. For self-consistent total energy calculations,
the convergence criterion was set to 10–7 Hartrees
for the crystal structure’s full relaxation (lattice and atomic
position optimizations). To evaluate the thermal contributions to
the enthalpy and free energy, we performed vibrational frequency analysis
at the DFT-D3/revPBE/DZVP level of theory under harmonic approximation.
The thermodynamic properties were then computed using the postprocessing
tool TAMkin.[39]
Results
and Discussion
Screening and Characterization
We
have screened various resolving agents that could form enantiospecific
cocrystals with S-ETI via grinding experiments (details
shown in Table S1). We found that S-ETI forms a cocrystal with S-2CLMA but
not with R-2CLMA. This is evidenced by the XRPD pattern
shown in Figure a.
The powder pattern of S-ETI:S-2CLMA
is significantly different from that of S-ETI and S-2CLMA, suggesting the formation of a new crystalline phase.
On the other hand, the powder pattern of S-ETI:R-2ClMA is comparable to that of S-ETI. Notice that the
peaks corresponding to R-2CLMA disappeared. This
is likely due to transformation into an amorphous phase due to the
excess energy produced or the increase in temperature during the grinding
experiment.[40,41] Nevertheless, this confirms that S-ETI:R-2CLMA is an enantiospecific cocrystal.
To further confirm this, we performed thermogravimetric analysis whose
results are shown in Figure b. Pure S-2CLMA and S-ETI
have similar melting temperatures, 119 and 117 °C, respectively,
whereas the cocrystal has a melting point of 98 °C, thereby confirming
the formation of a new phase.
Figure 1
(a) Powder X-ray diffraction patterns of S-ETI, S-2CLMA, and S-ETI:S-2CLMA
cocrystals and S-ETI:R-2CLMA. (b)
Melting temperatures of S-ETI, S-2CLMA, and S-ETI:S-2CLMA cocrystals
with 5 °C/min heating rate.
(a) Powder X-ray diffraction patterns of S-ETI, S-2CLMA, and S-ETI:S-2CLMA
cocrystals and S-ETI:R-2CLMA. (b)
Melting temperatures of S-ETI, S-2CLMA, and S-ETI:S-2CLMA cocrystals
with 5 °C/min heating rate.
Crystal Structure Analysis
To elucidate
the crystal structure of S-ETI:S-2CLMA, we performed single-crystal X-ray crystallography. To the
best of our knowledge, this is the first time that the crystal structure
of this cocrystal has been determined. The pertinent crystallographic
data in Table show
that S-ETI:R-2CLMA crystallizes
in the monoclinic P21 space group. Moreover,
the simulated peaks obtained from the single crystal exhibit excellent
correlation with the experimental powder pattern (Figure S2). This suggests that the bulk powder obtained by
batch crystallization is well-represented by the selected single crystal,
thus ruling out the presence of other phases or polymorphs in the
system. Furthermore, given that the system is enantiospecific, it
is expected that the counter-enantiomer (R-ETI:R-2CLMA) would have a similar structure by virtue of symmetry.
Table 1
Crystallographic Data and Refinement
Details of the S-ETI:S-2CLMA Cocrystal
crystal data
chemical
formula
C16H21ClN2O5
Mr
356.8
temperature (K)
100
crystal system
monoclinic
space group
P21
a, b, c (Å)
11.6912 (7), 5.7422 (4), 13.8421
(9)
α, β,
γ (deg)
90, 113.527 (2), 90
V (Å3)
852.02 (10)
Z
2
F (000)
376
density
calculated (g/cm3)
1.391
radiation type
Mo Kα (λ = 0.71073)
μ (mm–1)
0.253
crystal size (mm3)
0.62 × 0.19 × 0.08
data collection
diffractometer
Bruker D8 Venture
absorption correction
multiscan
(SADABS; Bruker, 2016)
Tmin, Tmax
0.681, 0.746
Rint
0.0325
refinement
goodness-of-fit on F2
1.057
R1, wR2 [I > = 2σ I]
0.028,
0.0688
R1, wR2 [all
data]
0.0322, 0.0707
no. of reflections
17 385
no. of parameters
222
Δρmax, Δρmin (e Å–3)
0.38, −0.21
Flack value
0.041
To understand
the underlying intermolecular interactions that stabilize
the cocrystal, we further examined its crystal structure. The asymmetric
unit in Figure a shows
a ring-like R22(8) H-bonding motif between S-ETI and S-2CLMA. This motif is visible
in the crystal packing along the ac-plane (Figure b) where S-ETI is shown
in red and S-2CLMA is shown in blue. The perspective
view along the same plane (Figure c) reveals that this ring-like motif propagates along
the b-direction, which is affirmed by the crystal
packing along the ab-plane exhibiting an infinite chain of H-bond
network. Analysis of the geometric parameters reveals four important
intermolecular H-bonding interactions reported in Table S4. The strongest of these is the 1.77 Å bond between
the carboxylic hydrogen of S-2CLMA and the amide
oxygen of S-ETI (Figure d). This is followed by the 1.99 Å bond
between the hydroxyl hydrogen of S-2CLMA and pyrrolidone
oxygen of S-ETI. The remaining H-bonds are due to
the interaction between the amide of the S-ETI and
the carboxylic oxygen of the S-2CLMA.
Figure 2
(a) Asymmetric unit of
the S-ETI:S-2CLMA cocrystal; (b)
packing along the ac-plane;
(c) perspective view along the ac-plane; and (d)
packing along the bc-plane.
(a) Asymmetric unit of
the S-ETI:S-2CLMA cocrystal; (b)
packing along the ac-plane;
(c) perspective view along the ac-plane; and (d)
packing along the bc-plane.
Molecular Simulations
To understand
why this cocrystal system behaves enantiospecifically, we generated
and ranked the most probable crystal structure of R-ETI:S-2CLMA (the less-stable diastereomeric cocrystal)
via molecular simulations, constrained within the most common space
groups for chiral cocrystals (i.e., P1, P1̅, P2, P21, P21/c, and P212121).[28] The resulting energy landscape is reported in Figure . For comparison, the experimental crystal
structures of enantiopure ETI, rac-ETI, S-2CLMA, and S-ETI:S-2CLMA are included.
From a thermodynamic perspective, a cocrystal would likely form if
its lattice energy is larger in magnitude than the sum of the lattice
energies of the coformers (the gray line in Figure ). Interestingly, two of the predicted structures
satisfy this threshold and are energetically close to the experimental S-ETI:S-2CLMA form (with around 2 and 4
kcal/mol difference, respectively, at the PM7 level of theory).
Figure 3
Energy landscape
of the predicted crystal structures of R-ETI:S-2CLMA (in ▲) in comparison
with experimental crystal structures (in ●) computed at the
semiempirical PM7 level of theory (at 25 °C, 1 bar). The critical
lattice energy (gray dashed line) is set as the sum of the conformer’s
lattice energy (enantiopure ETI plus S-2CLMA). The
color corresponds to the space group.
Energy landscape
of the predicted crystal structures of R-ETI:S-2CLMA (in ▲) in comparison
with experimental crystal structures (in ●) computed at the
semiempirical PM7 level of theory (at 25 °C, 1 bar). The critical
lattice energy (gray dashed line) is set as the sum of the conformer’s
lattice energy (enantiopure ETI plus S-2CLMA). The
color corresponds to the space group.To refine the structure of the most stable hypothetical structure,
we further relaxed its structure at the DFT-D3/revPBE/DZVP level of
theory with periodic boundary conditions. Note that the dispersion-corrected
DFT is generally considered more accurate than semiempirical PM7 but
comes with a greater computational cost. The resulting hypothetical
structure in comparison with the DFT-optimized experimental structure
of the other stereoisomer is shown in Figure . Moreover, the two crystal structures are
remarkably similar as evidenced by the resemblance of their simulated
powder pattern (Figure S3).
Figure 4
DFT-optimized crystal
structures of (a) hypothetical R-ETI:S-2CLMA and (b) experimental S-ETI:S-2CLMA. The H-bond lengths (hydrogen to acceptor)
are shown in angstroms, and the chiral centers are indicated accordingly.
DFT-optimized crystal
structures of (a) hypothetical R-ETI:S-2CLMA and (b) experimental S-ETI:S-2CLMA. The H-bond lengths (hydrogen to acceptor)
are shown in angstroms, and the chiral centers are indicated accordingly.To evaluate the stabilities of the crystal structures
at various
temperatures, we performed vibrational analysis at the DFT-D3/revPBE/DZVP
level of theory together with harmonic approximation. The difference
in enthalpy ΔH and free energy ΔG between the predicted hypothetical structure (R-ETI:S-2CLMA) and the experimental structure
(S-ETI:S-2CLMA) is reported in Figure S4. Interestingly, although the two crystal
structures are remarkably similar, their stabilities are markedly
different. At the selected temperature range, ΔH remains relatively constant at around −5.5 kcal/mol, which
confirms that the experimentally observed cocrystal has stronger bond
energies. The flat variation of ΔH with temperature
suggests that the two cocrystals have similar specific heat capacities.
On the other hand, ΔG is negative and increases
with temperature, implying that the hypothetical structure is entropically
favored (more disordered).Consequently, the two cocrystals
would have a closer magnitude
of free energy at higher temperatures (below the melting point). This
supports the idea that the strength of stereospecific interactions
is highly directional; thus, such interactions would diminish when
molecular vibration increases.With such a difference in stability
despite having a similar crystal
packing, one might expect that the H-bond interaction distances of
the predicted R-ETI:S-2CLMA cocrystal
must be systematically longer than those of the stable S-ETI:S-2CLMA cocrystal. However, as shown in Figure , this is not the
case, as some H-bonds of the unstable cocrystal are shorter. To further
investigate this, we employed the Hirshfeld surface analysis, which
is a popular approach to quantify differences in intermolecular interactions
as implemented in CrystalExplorer.[42] The
Hirshfeld surface can be defined as a region of space surrounding
a particular molecule where its contribution to the total electron
density is equal to that of its surroundings.[43] Intermolecular interactions can then be visualized by mapping the
color of the surface with the normalized contact distance, dnorm, which compares the distance between two
atoms across the surface to the combined van der Waals radii of the
atoms.The Hirshfeld surfaces of both cocrystals are shown in Figure a,b, and the corresponding
fingerprint plots are shown in Figure c,d (Hirshfeld analysis of each atomic interaction
is provided in Figure S5). The conspicuous
red regions on the surface (close contacts) are due to O···H
contacts, which appear as spikes (encircled in red) in the fingerprint
plot. One notable difference between the two fingerprints is the occurrence
of a small H···H spike in R-ETI:S-2CLMA, which does not occur in S-ETI: S-2CLMA. As a result, the H···H contribution
on the Hirshfeld surface is slightly higher in R-ETI: S-2CLMA, as shown in Figure e, while the others (O···H, C···H,
Cl···H) are essentially the same. With this, one might
speculate that the H···H repulsion is the reason for
the lower stability of R-ETI:S-2CLMA.
However, the sum of di and de for the closest H···H contact is around
2.4 Å, which is within the range of attractive dispersion interactions
for H···H interactions. Thus, this could not explain
the observed difference in stability.
Figure 5
Hirshfeld surfaces of S-2CLMA in the cocrystals (a) R-ETI:S-2CLMA and
(b) S-ETI:S-2CLMA and the corresponding
2D fingerprint plot of (c) R-ETI:S-2CLMA and (d) S-ETI:S-2CLMA (interior
distance di and exterior distance de are in angstroms) and (e) comparison of contribution
(in %) of selected close contacts to the Hirshfeld surface.
Hirshfeld surfaces of S-2CLMA in the cocrystals (a) R-ETI:S-2CLMA and
(b) S-ETI:S-2CLMA and the corresponding
2D fingerprint plot of (c) R-ETI:S-2CLMA and (d) S-ETI:S-2CLMA (interior
distance di and exterior distance de are in angstroms) and (e) comparison of contribution
(in %) of selected close contacts to the Hirshfeld surface.Upon further inspection of the structure, we observed
that the
centroid-to-centroid distance between phenyl rings of S-2CLMA is longer in R-ETI:S-2CLMA
than in S-ETI:S-2CLMA, as shown
in Figure .
Figure 6
T-shape aromatic
interactions (magenta) and CH−π interaction
(orange) in (a) R-ETI:S-2CLMA and
(b) S-ETI:S-2CLMA. The angle between
the ring normal is around 71° for both.
T-shape aromatic
interactions (magenta) and CH−π interaction
(orange) in (a) R-ETI:S-2CLMA and
(b) S-ETI:S-2CLMA. The angle between
the ring normal is around 71° for both.Note that the T-shape aromatic interaction (also known as the edge-to-face
interaction) occurs when the distance between the ring centroids is
around 5 Å and when the angle between the ring normals is greater
than 50°.[44,45] On the other hand, the CH−π
interaction occurs when a H attached to C has a distance of less than
3 Å from the aromatic ring centroid.[46] These definitions for T-shape aromatic interactions and CH−π
interactions are also consistent with those of the PLATON program.[47] To quantify the strength of the T-shape aromatic
interaction, we used the CCDC’s Aromatic Analyzer as implemented in Mercury,[48] which is
based on a neural network model. From the distances between ring centroids
and the relative orientation (angle between the ring normals), it
calculates an interaction score ranging from 0 (no interaction) to
10 (strong interaction). Indeed, the aromatic interaction score of
the stable S-ETI:S-2CLMA is higher
than that of the predicted R-ETI:S-2CLMA cocrystal (Table S5), illustrating
the important role of T-shape aromatic interactions and CH−π
interactions in the stability of these cocrystals. Thus, we postulate
that due to the change in the chirality of ETI in R-ETI:S-2CLMA, S-2CLMA would have
to rotate the functional groups attached to its chiral center (−OH
and −COOH groups) to maximize the H-bond interactions. However,
in the process, the phenyl rings would have to reorient in a way that
reduces the strength of T-shape aromatic interactions. This makes
the alternative cocrystal less stable as supported by the lower lattice
energy. Overall, our simulations reveal molecular-level insights that
could rationalize the observed enantiospecific behavior of this cocrystal
system.Since many polymorphs
of racemic ETI[49] have been found, the synthesized RS-ETI (form II) that we used in the separation experiment
is confirmed by XRPD and NMR, as shown in Figures S6 and S7, respectively. The enantioseparation of S-ETI from its racemate was performed in acetonitrile with S-2CLMA as a coformer. Enantiomeric excess and yield of
the product are defined in eqs and 2, respectively.S-ETI:S-2CLMA is an incongruent cocrystal system due to the huge differences
of the solubility of the two species in acetonitrile. Therefore, an
equal ratio of S-ETI and S-2CLMA
is not suitable for the production of the cocrystal. Varying the initial
composition ratio between the API and coformer is then vital to obtain
the optimum cocrystallization outcome.Results show that a 1:1
ratio of rac-ETI and S-2CLMA is the optimal ratio
since the resolution was achieved efficiently
with an excellent purity (97% ee) and satisfactory yield (70%) of S-ETI, as shown in Table . Note that this is a 2:1 ratio of S-2CLMA:S-ETI. Increasing the amount of S-2CLMA further does not improve the experimental yield of S-ETI since S-2CLMA will crystallize together
with the S-ETI:S-2CLMA cocrystal.
This could be explained by a schematic ternary phase diagram, as shown
in Figure S8, where the operation conditions
exceed the region that allows only the cocrystal to crystallize as
a stable phase. Alternatively, reducing the amount of S-2CLMA to be 0.5 times by mole of rac-ETI (1:1 ratio
of cocrystal) is not favorable since only rac-ETI
was acquired as a solid phase at this point. This is because of the
differences in the solubility of S-2CLMA that was
about 10 times higher than that of S-ETI in acetonitrile
(Table S3). Therefore, at this ratio, pure RS-ETI is the most stable solid phase. Finally, the purity
of the desired product (S-ETI) in all cases is considerably
unchanged because the system is enantiosepecific, which means that
only one enantiomer (S-ETI) cocrystallizes together
with S-2CLMA.
Table 2
Enantiomeric Excess
and Experimental
Yield of Chiral Resolution Using S-2CLMA When Varying
the Molar Ratio of RS-ETI and S-2CLMA
initial
composition
final
solid composition (HPLC)
ratio
RS-ETI (mg)
S-2CLMA (mg)
ACN (mL)
CoCry.
weight (mg)
% ee (S-ETI)
S-ETIa (mg)
experimental yield (%) (based
on S-ETI)
1:1
114
125
0.5
81.5
96.7
39.4
69.1
1:1.5
114
187
0.5
68.0
97.0
36.8
64.6
1:2
114
250
0.5
57.8
98.1
27.0
47.4
The total weight of the cocrystal
was measured after washing and drying. The amount of S-ETI, R-ETI, and %ee was calculated based on the
total weight of the cocrystal and ETI composition in the cocrystal
by chiral HPLC following eqs and 2.
The total weight of the cocrystal
was measured after washing and drying. The amount of S-ETI, R-ETI, and %ee was calculated based on the
total weight of the cocrystal and ETI composition in the cocrystal
by chiral HPLC following eqs and 2.
Conclusions
In this
work, we demonstrate the enantiospecific cocrystallization
of etiracetam (ETI) with 2-chloromandelic acid (2-CLMA).
In this system, S-2CLMA forms a cocrystal with S-ETI but not with R-ETI. The crystal structure
of the new cocrystal has been determined and analyzed. Exploiting
the enantiospecific cocrystallization behavior, we showed that the
resolution of S-ETI from rac-ETI can be achieved
efficiently with 96.7% purity and 69.1% yield. To understand why the R-ETI:S-2CLMA cocrystal does not form,
we employed crystal structure prediction and molecular simulations.
Although the predicted hypothetical structure of R-ETI:S-2CLMA is strikingly similar to that of the
experimentally observed R-ETI:S-2CLMA,
a large lattice energy difference of 5.5 kcal/mol per cocrystal formula
unit was obtained. While both cocrystals have relatively similar H-bonding
geometries and Hirshfeld fingerprints, we found that the aromatic
interactions in S-ETI:S-2CLMA are
more favorable than in R-ETI:S-2CLMA,
leading to the observed enantiospecific behavior.For further
process design, all compounds in the cocrystallization
process could be recycled after the first crystallization stage. In
the experiment, S-2CLMA can be recycled practicably
by washing from the surface of the solid cocrystal with diethyl ether,
drying to remove the solvent, and adding back to the reactor, accordingly.
For R-ETI, racemization could be a process to prepare
a racemic solution from the remaining enriched solution and then use
it further in the next batch of cocrystallization.
Authors: Christelle Herman; Valérie Vermylen; Bernadette Norberg; Johan Wouters; Tom Leyssens Journal: Acta Crystallogr B Struct Sci Cryst Eng Mater Date: 2013-06-22